{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016670","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.464374+00:00","generated_at":"2026-06-24T00:42:21.114622+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"aTyr Pharma gets FDA Fast Track for efzofitimod in pulmonary sarcoidosis","bullets":["FDA granted Fast Track designation on August 9, 2022 for lead candidate efzofitimod.","Fast Track aims to expedite development and review; may allow rolling submission.","Pulmonary sarcoidosis is a major interstitial lung disease with no approved therapies.","Efzofitimod is a novel immunomodulator targeting neuropilin-2; Phase 3 trial ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016670","json":"https://secwatch.observer/filing/0000950170-22-016670.json","markdown":"https://secwatch.observer/filing/0000950170-22-016670.md","text":"https://secwatch.observer/filing/0000950170-22-016670.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/0000950170-22-016670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017022016670/life-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:42:21.114622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}